Career Advisor

Oncology Career Guide and Counseling

We can help you connect with ministry contacts who can provide more information about oncology career streams, and who are knowledgeable about current and future hiring needs and oncology career development in these areas. Contact us to find out more about oncology career path, oncology career planning, oncology career assessment and oncology career choices. what oncology career opportunities may be just around the corner and how you can build a satisfying future.

Question: What is the risk to cancer (oncology) nurses from working with dangerous chemotherapy drugs? What is the risk to nurses working in the cancer field (oncology) due to their proximity to cancer causing drugs and radiation and chemotherapy? I am hearing stories of many oncology nurses loosing their hair?

Answer: Yes, proper precautions are very important among the exposed health personnel as anti-neoplastic agents and radiation are known occupational hazards. The following health effects have been reported in hospital workers exposed to antineoplastic agents: diarrhea, abdominal pain, dizziness, nausea, skin rashes, hair loss, adverse reproductive effects such as disruption of menstrual cycle, fetal loss, and birth defects, etc.


Oncology Career Information and Opportunities

Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities

MarketWatch (press release)
HACKENSACK, NJ, May 18, 2012 /PRNewswire via COMTEX/ -- Champions Oncology Inc. (OBB:CSBR) announced today that it has received US Clinical Laboratory Improvement Amendment (CLIA) certification from the Maryland Department of Health and Mental Hygiene ...
 

U.S. News & World Report

ZYTIGAź (abiraterone acetate) Data to be Presented at 2012 American Society of ...
MarketWatch (press release)
 

Wall Street Journal

Children with Cancer Have Complete Responses in a Children's Oncology Group ...
MarketWatch (press release)
 

Amgen Presents Oncology Data

Zacks.com
Amgen (AMGN - Analyst Report) recently presented additional data on its oncology candidate, blinatumomab (AMG 103). The company presented results from a phase II single-arm dose-ranging study which showed that 72% of patients achieved a high rate of ...
 

Amgen Presents Oncology Data - Analyst Blog

NASDAQ
Amgen ( AMGN ) recently presented additional data on its oncology candidate, blinatumomab (AMG 103). The company presented results from a phase II single-arm dose-ranging study which showed that 72% of patients achieved a high rate of complete response ...
 

BNP Paribas and NCCS present Singapore's first regional surgical oncology ...

The FINANCIAL
The FINANCIAL -- BNP Paribas and The National Cancer Centre Singapore launch the first NCCS Surgical Oncology Conference in Singapore to be held at NCCS from 16 to 18 May 2012. This inaugural conference is part of NCCS' drive to not only become a ...
 

Bavarian Nordic to Report New PROSTVACR Clinical Data at the American Society ...

Reuters
In oncology, the company's lead program is PROSTVACR , a therapeutic vaccine candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 trial and is being developed under a collaboration agreement with the National Cancer ...
 

Generex Augments Antigen Express Scientific Advisory Board

MarketWatch (press release)
After completing a medical oncology fellowship at the Dana-Farber Cancer Institute, he joined the faculty of the Women's Cancer Program at Dana-Farber and Harvard Medical School where he is now an Assistant Professor of Medicine and Director of ...
 

Ruga Corporation Acquires a Novel B-RAF Paradox Breaker Program from Selexagen ...

MarketWatch (press release)
PALO ALTO, Calif., May 17, 2012 /PRNewswire via COMTEX/ -- Ruga Corporation, a privately held oncology company focused on the discovery and development of personalized therapeutics targeting tumor-selective adaptive responses, announced today that as ...
 

Cyclacel to Report New Sapacitabine Clinical Data at the American Society of ...

MarketWatch (press release)
In June 2011 at the Annual Meeting of the American Society of Clinical Oncology (ASCO), Cyclacel reported data from a pilot Phase 1/2 study including promising response rate, low 4-week and 8-week mortality in elderly patients with AML aged 70 years or ...